Increased matrix metalloproteinase-9 (MMP-9) expression is associated with intimal hyperplasia in saphenous vein (SV) bypass grafts. Recent evidence suggests that HMG-CoA reductase inhibitors (statins) can prevent the progression of vein graft failure. Here we investigated whether statins inhibited MMP-9 secretion from cultured human SV smooth muscle cells (SMC) and examined the underlying mechanisms. SV-SMC from different patients were exposed to phorbol ester (TPA) or PDGF-BB plus interleukin-1α (IL-1). MMP-9 secretion and mRNA expression were analyzed using gelatin zymography and RT-PCR, respectively. Specific signal transduction pathways were investigated by immunoblotting and pharmacological inhibition. Simvastatin reduced TPA-and PDGF/IL-1-induced MMP-9 secretion and mRNA levels, effects reversed by geranylgeranyl pyrophosphate and mimicked by inhibiting Rho geranylgeranylation or Rho-kinase (ROCK). MMP-9 secretion induced by PDGF/IL-1 was mediated via the ERK, p38 MAPK, and NFκB pathways, whereas that induced by TPA was mediated specifically via the ERK pathway. Simvastatin failed to inhibit activation of these signaling pathways. Moreover, simvastatin did not affect MMP-9 mRNA stability. Together these data suggest that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on signaling pathways required for MMP-9 gene expression.
agent has yet proven effective in man. However, there is good evidence emerging that 3-hydroxy-3-methylglutaryl CoA reductase inhibitors (statins) can reduce SV graft occlusions and improve cardiovascular outcome after CABG (3), irrespective of whether treatment is initiated pre-(2, 4) or post-(5, 6) operatively.
Statins are commonly prescribed cholesterol-lowering drugs that significantly improve the morbidity and mortality associated with atherosclerosis (7) . Moreover, their clinical benefits appear greater than would be expected from simply lowering cholesterol, and it is becoming increasingly clear that these agents have favorable pleiotropic effects that are unrelated to lipidlowering (8) . For example, a number of animal studies have reported that statins reduce neointima formation following arterial injury independently of cholesterol-lowering (9) (10) (11) . Statins act by inhibiting synthesis of intracellular mevalonate which, in addition to its central role in cholesterol synthesis, is also a precursor of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), isoprenoids required for prenylation of Ras and Rho-family GTPases, respectively (12) . This ability of statins to inhibit the prenylation and resultant activity of small GTPases may underlie many of their cholesterol-independent effects.
The pathological lesion of stenosis is intimal hyperplasia, a complex process initiated in the vessel wall as a consequence of bypass grafting. Although the etiology of vein graft intimal hyperplasia is multifactorial, smooth muscle cell (SMC) proliferation and migration are key events in its development (13) . Importantly, both proliferation and migration of SMC require secretion of specific matrix-degrading metalloproteinases, particularly, the gelatinases MMP-2 and MMP-9 (14, 15) . Indeed, two recent studies in MMP-9 knockout mice have established that MMP-9 secretion is essential for proliferation and migration of SMC and development of intimal hyperplasia following balloon injury (16, 17) . MMP-9 expression is increased during neointima formation in in vivo experimental vein grafts (18, 19) and in in vitro organ-cultured human SV (20) (21) (22) , and furthermore, neointima formation in organ-cultured human SV is attenuated by MMP inhibition (21) .
We have recently reported that a commonly prescribed statin, simvastatin, inhibits neointimal development in organ-cultured human SV, with an associated reduction in tissue levels of MMP-9 (23). Additionally, we demonstrated that migration of SV-SMC through a Matrigel basement membrane, an MMP-dependent event, was also inhibited by simvastatin (23). The present study was designed to determine whether simvastatin can directly inhibit MMP-9 secretion from cultured human SV-SMC, and if so, to investigate the intracellular mechanisms responsible.
MATERIALS AND METHODS

Materials
All cell culture reagents were purchased from Invitrogen (Paisley, UK), except fetal calf serum (FCS), which was from Biowest Ltd. (Ringmer, East Sussex, UK). Simvastatin was a gift from Merck, Sharpe and Dohme (Hoddesdon, Herts., UK) and was activated by alkaline hydrolysis (24). 12-O-tetradecanoylphorbol 13-acetate (TPA), platelet-derived growth factor-BB (PDGF), interleukin-1α (IL-1), mevalonate, and Actinomycin D were purchased from Sigma (Poole, Dorset, UK). GGPP, FPP, and LY294002 were from Alexis Biochemicals (Nottingham, UK) and atorvastatin, lovastatin, pravastatin, GGTI-286, Y27632, rhotekin-RBD, PD98059, SB203580, and MG-132 were from Calbiochem (Nottingham, UK). RhoA antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture
SMC were cultured from human SV using an explant technique, as we have described previously (23). Local ethical committee approval and informed patient consent were obtained. Experiments were performed on passage 2-4 cells from different patients.
Gelatin zymography
SMC were exposed to serum-free medium (SFM) for 48 h and then incubated in fresh medium containing 0.4% FCS and appropriate supplements for a further 48 h. Conditioned media (CM) were collected, detached cells were removed by centrifugation, and gelatin zymography was performed as we have described previously (23). As a positive control, CM from HT-1080 cells was also loaded onto each gel. The relative density of each gelatinolytic band was determined from negative scanned images of gels using ImageQuant software (Amersham Life Science, Amersham, Bucks, UK).
Semi-quantitative RT-PCR
SMC were serum-starved for 48 h and then treated with fresh medium containing 0.4% FCS with appropriate supplements. Cellular RNA was extracted and RT-PCR was performed as we have described previously (25). MMP-9 forward (5′-TTCATCTTCCAAGGCCAATC-3′) and reverse (5′-CTTGTCGCTGTCAAAGTTCG-3′) primers and GAPDH forward (5′-TGATGACATCAAGAAGGTGGTGAAG-3′) and reverse (5′-TCCTTGGAGGCCATGTGGGCCAT-3′) primers were synthesized by Invitrogen. PCR conditions comprised 30 cycles (MMP-9) or 25 cycles (GAPDH) of 94°C (30 s), 60°C (1 min) and 72°C (1 min). PCR products were resolved by 2% agarose gel electrophoresis, and the relative intensity of MMP-9 (287 bp) and GAPDH (240 bp) bands determined following ethidium bromide staining using a Typhoon 9410 Imager and ImageQuant software (Amersham Life Science). Reactions were optimized for the linear phase of PCR by serial dilution of RNA to ensure that band intensity was proportional to the amount of RNA template. Samples were then standardized for equal expression of GAPDH.
RhoA activation assay
Serum-starved cells were exposed to 0.4% FCS-containing medium alone or supplemented with PDGF/IL-1 or TPA for 20 min before preparing cell lysates (26). RhoA activation was determined using a rhotekin Rho binding domain affinity precipitation assay, followed by immunoblotting with RhoA antibody, as we have described previously (26).
Immunoblotting
Serum-starved SMC were exposed to SFM containing appropriate supplements before preparing whole cell homogenates and immunoblotting, as we have described previously (27) . Activation of the extracellular signal-regulated kinases (ERK-1/2), p38 mitogen-activated protein kinase (p38 MAPK), c-Jun NH 2 -terminal kinase (JNK), phosphoinositide 3-kinase (PI3K)/Akt and nuclear factor-κB (NF-κB) pathways was determined using phospho-specific antibodies (Cell Signaling Technology, Hitchin, Herts., UK) for ERK-1/2 (Thr202/Tyr204), p38 MAPK (Thr180/Tyr182), JNK (Thr183/Tyr185), Akt (Ser473), and IκB-α (Ser32), respectively. Equal sample loading was confirmed using α-smooth muscle actin (α-SMA) antibody (Sigma).
Statistical analysis
All results are expressed as means ± SEM with n representing the number of different patients. Differences between treatment groups were analyzed using paired t-tests. Dose response data were compared using repeated measures of one-way ANOVA (ANOVA) and Newman-Keuls post hoc test. P < 0.05 was considered statistically significant.
RESULTS
Simvastatin inhibits MMP-9 secretion via inhibition of the RhoA/ROCK pathway
We employed gelatin zymography to determine the effects of simvastatin on gelatinase secretion from human SV-SMC induced by the phorbol ester TPA (100 nM) or by a combination of 15 ng/ml PDGF plus 20 ng/ml IL-1α (PDGF/IL-1). Simvastatin (0.5-10 µM) significantly reduced both TPA-and PDGF/IL-1-induced MMP-9 secretion in a concentration-dependent manner ( Fig.  1 ). In contrast, MMP-2 was constitutively secreted and was not affected by TPA, PDGF/IL-1 or simvastatin treatment ( Fig. 1A and data not shown). All subsequent experiments were performed with 10 µM simvastatin.
To determine whether this effect of simvastatin could be mimicked by all statins, we investigated whether other lipophilic (atorvastatin, lovastatin) or hydrophilic (pravastatin) statins could also inhibit TPA-induced MMP-9 secretion (Fig. 1C) . Although 10 µM atorvastatin was consistently more potent than 10 µM simvastatin, on no occasion did we observe any inhibitory effect of lovastatin or pravastatin at this concentration ( Fig. 1C) . Indeed, no inhibition of MMP-9 secretion was observed with these two statins even at concentrations up to 20 µM (data not shown). In keeping with our observation with simvastatin, none of the additional statins tested had any effect on MMP-2 secretion (data not shown).
We then investigated whether simvastatin was acting via inhibition of protein prenylation. As expected, coincubation of simvastatin-treated cells with 100 µM mevalonate prevented its inhibitory effects on either TPA-( Fig. 2A) or PDGF/IL-1-(data not shown) induced MMP-9 secretion. A similar effect was observed following supplementation with 10 µM GGPP, but not 10 µM FPP ( Fig. 2A ), indicating that simvastatin was reducing MMP-9 secretion via inhibition of Rho geranylgeranylation.
To confirm that geranylgeranylation of Rho-family GTPases was essential for MMP-9 secretion, we investigated the effects of GGTI-286, a specific inhibitor of geranylgeranyl transferase-I (GGTase-I). GGTI-286 (10 µM) mimicked the inhibitory effect of simvastatin on MMP-9 secretion (Fig. 2B) , indicating a role for inhibition of Rho-family GTPases. Although the Rhofamily of GTPases comprises three main subfamilies (Rho, Rac, cdc42), it is only RhoA that activates Rho-kinase (ROCK) (28). Consistent with the effects of both simvastatin and GGTI-286, the ROCK inhibitor Y27632 (10 µM) also reduced MMP-9 secretion (Fig. 2B) .
Collectively, these data suggest that inhibition of MMP-9 secretion by simvastatin occurs via inhibition of the RhoA/ROCK pathway in SV-SMC.
To determine whether PDGF/IL-1 or TPA treatment activated RhoA, we performed rhotekin affinity precipitation assays. A significant level of RhoA activation was observed in control (0.4% FCS-treated) cells, but no further increase was observed in response to either PDGF/IL-1 or TPA treatment (Fig. 2C) .
Simvastatin reduces MMP-9 mRNA levels via inhibition of the RhoA/ROCK pathway Using semiquantitative RT-PCR, we then investigated whether simvastatin was affecting MMP-9 at the mRNA level. The MMP-9 PCR product was undetectable in unstimulated cells, but was increased following TPA treatment, with peak levels observed after 28 h (Fig. 3A) . Simvastatin markedly reduced mRNA levels at all time points studied (Fig. 3A) . Gelatin zymography of CM from the same experiments revealed a similar inhibitory profile on MMP-9 secretion (Fig. 3B) .
Comparison of the areas under the curves (Fig. 3A and 3B) showed that simvastatin inhibited the total amount of TPA-induced MMP-9 mRNA and MMP-9 secretion over a 40-h period by 52.6 ± 11.6% (P<0.05, n=4) and 57.8±3.7% (P<0.001, n=4), respectively. Similarly, we determined that PDGF/IL-1-induced MMP-9 mRNA levels were also reduced by simvastatin (Fig. 4A ). Our data therefore indicate that the inhibitory effect of simvastatin on MMP-9 secretion occurs at the level of mRNA and that changes in mRNA levels correlate with those of secretion.
To further support these observations, and in agreement with the observed effects on MMP-9 secretion (Fig. 2B ), we were able to mimic the inhibitory effects of simvastatin on MMP-9 mRNA levels with the GGTase-I inhibitor GGTI-286 or the ROCK inhibitor Y27632 (Fig. 4B) , indicating a mechanism involving inhibition of RhoA and ROCK.
Simvastatin does not inhibit signal transduction pathways required for MMP-9 expression
MMP-9 gene expression can be activated via a number of signal transduction pathways, including those involving ERK-1/2, p38 MAPK, JNK, PI3K/Akt, and NF-κB (29-34). To determine whether these signaling pathways were activated by PDGF/IL-1 and TPA in human SV-SMC, we performed immunoblotting experiments with phospho-specific antibodies (Fig. 5) . PDGF/IL-1 treatment activated the ERK, p38 MAPK, PI3K/Akt, and NFκB pathways, but had no effect on JNK activation. In contrast, TPA activated only the ERK pathway.
We next determined which of these signal transduction pathways were required for PDGF/IL-1-and TPA-induced MMP-9 secretion. PDGF/IL-1-induced MMP-9 secretion was inhibited by selective inhibitors of the ERK (30 µM PD98059), p38 MAPK (20 µM SB203580) or NF-κB (5 µM MG-132) pathways, but not by inhibition of the PI3K/Akt pathway (10 µM LY294002) (Fig.  6 ). In addition, TPA-induced MMP-9 secretion was inhibited by PD98059 (Fig. 6 ).
Finally, we investigated whether simvastatin was reducing MMP-9 secretion by preventing activation of the ERK, p38 MAPK, PI3K/Akt or NFκB pathways (Fig. 7) . Surprisingly, simvastatin had no inhibitory effect on any of the signaling pathways studied. However, in keeping with this observation, neither GGTase-I nor ROCK inhibition had any effect (Fig. 7) . Thus, although the RhoA/ROCK pathway is inhibited by simvastatin in human SV-SMC, it appears not to be required for activation of the signal transduction pathways coupled to MMP-9 secretion.
Simvastatin does not reduce MMP-9 mRNA stability
Recent studies have demonstrated that MMP-9 mRNA levels can be regulated posttranscriptionally at the level of mRNA stability (35, 36) . We, therefore, investigated whether simvastatin was reducing MMP-9 mRNA levels by increasing the rate of mRNA degradation. SV-SMC were pretreated with TPA for 24 h to stimulate MMP-9 mRNA synthesis before blocking any further transcription with 5 µg/ml Actinomycin D (in the presence of simvastatin or vehicle) for a further 8-16 h. Simvastatin did not reduce MMP-9 mRNA levels in the presence of Actinomycin D (Fig. 8) , indicating that its suppressive effect on mRNA levels was not the result of increased mRNA degradation.
DISCUSSION
We have previously shown that simvastatin inhibits neointima formation in organ-cultured human SV, with a concomitant decrease in tissue MMP-9 expression (23). Furthermore, simvastatin inhibited both proliferation and invasion of cultured human SV-SMC (23), two pivotal events in neointimal development. As SMC invasion requires MMP activity (23), we sought to determine whether our earlier report of an inhibitory effect of simvastatin on SV-SMC invasion might be attributable to direct inhibition of MMP-9 secretion. Our current data demonstrate that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on the signal transduction pathways required for MMP-9 expression.
The inhibition of MMP-9 secretion was more pronounced with atorvastatin than simvastatin, likely reflecting its increased potency relative to simvastatin (37) . However, neither lovastatin nor pravastatin reduced MMP-9 secretion, even at concentrations up to 20 µM. This was a surprising observation and suggests that different statins may vary in their potencies toward particular aspects of human SV-SMC function, such as the regulation of MMP-9 secretion. Indeed, such variance in the cholesterol-independent effects of statins may contribute to their differential effectiveness in clinical studies (38) .
Earlier studies in other cell types have reported opposing effects of statins on MMP-9 mRNA levels. Although statins reduced MMP-9 mRNA levels in fibroblasts (39) and breast carcinoma cells (40) , increased levels were observed in macrophages (41). Luan et al. (42) recently reported that lovastatin reduced MMP-9 secretion from human SV-SMC and rabbit aortic SMC, although no effect on MMP-9 mRNA levels was observed in the rabbit cells. Unfortunately, the effects of lovastatin on MMP-9 mRNA levels were not investigated in human SV-SMC. Importantly, in that same study, statin treatment also inhibited secretion of MMPs 1, 2, and 3, which is indicative of a nonselective post-translational mechanism common to several MMPs. These results obtained in rabbit aortic SMC (42) clearly differ from those of our present study using human SV-SMC, in which simvastatin markedly reduced MMP-9 mRNA levels but had no effect on MMP-2 secretion. However, our present results accord with those in our previous report, in which simvastatin specifically reduced MMP-9 expression in organ-cultured human SV but had no effect on MMP-2 expression (23). The disparity between our results and those of Luan et al. might well be due to interspecies variation and/or the source of SMC used (rabbit aorta vs. human SV).
One mechanism by which statins may reduce MMP-9 mRNA levels is to inhibit the signal transduction pathways coupled to MMP-9 gene expression. For example, recent studies in vascular SMC have shown that statins can inhibit the ERK (43-45) and NF-κB (46, 47) pathways. In the present study in SV-SMC, simvastatin did not inhibit either PDGF/IL-1-induced ERK, p38 MAPK, or NF-κB activation, or TPA-induced ERK activation, all of which were necessary for MMP-9 expression. Furthermore, inhibition of the RhoA/ROCK pathway also failed to affect these signaling pathways, indicating that RhoA and ROCK are not upstream activators of these pathways. Indeed, RhoA was not activated by either PDGF/IL-1 or TPA, although significant basal RhoA activity was consistently detected in unstimulated cells. In agreement with our present findings, it has previously been reported that simvastatin inhibits proliferation of human vascular SMC via inhibition of RhoA, but without affecting ERK or p38 MAPK activation (48) .
It is well established that statins increase nitric oxide synthesis (49, 50) , reportedly due to inhibition of the RhoA/ROCK pathway (51, 52) . As increases in nitric oxide have recently been shown to reduce MMP-9 mRNA stability (35, 36) we investigated whether the simvastatininduced reduction in MMP-9 mRNA levels in human SV-SMC might occur via the same mechanism. However, our studies using Actinomycin D clearly demonstrated that simvastatin had no effect on MMP-9 mRNA stability, thereby suggesting that its effects are more likely to be at the level of reducing MMP-9 gene transcription.
The precise mechanism by which simvastatin inhibits MMP-9 secretion from human SV-SMC requires further detailed study. Our present data demonstrate that the inhibitory effect of simvastatin occurs via inhibition of the RhoA/ROCK pathway and is the result of decreased MMP-9 mRNA levels. The mechanism by which RhoA/ROCK inhibition leads to a reduction in MMP-9 mRNA levels is likely to be at the transcriptional level, possibly as a result of reduced transcription factor binding. It has been reported that statins can reduce MMP-9 gene transcription in fibroblasts via inhibition of AP-1 and NF-κB activity, although this occurred via a Ras-dependent mechanism (39) , in contrast to the RhoA-dependent mechanism we describe here. Our observation that simvastatin reduced MMP-9 mRNA levels and secretion, induced by either PDGF/IL-1 or TPA, indicates a mechanism common to both stimuli. As only PDGF/IL-1 activated the NF-κB pathway, the effects on this transcription factor are unlikely to explain the effects of simvastatin in human SV-SMC. Alternatively, simvastatin may be increasing binding of a transcriptional repressor. For example, statins have recently been shown to reduce IL-8 mRNA levels in mononuclear cells via increased activity of the Oct-1 repressor (53) . Although the human MMP-9 promoter does not contain an Oct-1 consensus site (our unpublished observations), it is feasible that statins may target alternative transcriptional repressors that bind to the MMP-9 promoter.
The present study supports and extends our previous report on the potential beneficial effects of simvastatin on vascular remodeling in SV bypass grafts (23). Although some caution is required in extrapolating in vitro observations to the clinical scenario, a particular strength of our study lies in the use of SMC cultured from human SV, the exact tissue in which graft stenosis develops in vivo.
In summary, simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on the signal transduction pathways required for MMP-9 expression (summarized in Fig. 9 ). The ability of simvastatin to reduce MMP-9 secretion from SV-SMC may contribute to its cholesterolindependent clinical benefits in reducing the incidence of SV graft failure in man.
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